-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by StockNews.com
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by StockNews.com
Research analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "sell" rating on the stock.
BiondVax Pharmaceuticals Trading Up 7.6 %
NASDAQ BVXV opened at $2.82 on Monday. The business's fifty day moving average is $6.78 and its 200-day moving average is $8.93. The company has a debt-to-equity ratio of 5.92, a current ratio of 5.76 and a quick ratio of 5.76. The stock has a market capitalization of $4.04 million, a price-to-earnings ratio of -0.70 and a beta of 2.65. BiondVax Pharmaceuticals has a one year low of $2.37 and a one year high of $22.90.
Get BiondVax Pharmaceuticals alerts:BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its quarterly earnings data on Wednesday, November 30th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Equities research analysts predict that BiondVax Pharmaceuticals will post -0.3 EPS for the current year.
Hedge Funds Weigh In On BiondVax Pharmaceuticals
An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. grew its position in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 163,423 shares of the company's stock after buying an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.BiondVax Pharmaceuticals Company Profile
(Get Rating)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
See Also
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Research analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "sell" rating on the stock.
StockNews.com的研究分析师开始报道以下股票 BiondVax Pharmicals(纳斯达克股票代码:BVXV — 获取评级) 在周一发布给客户和投资者的研究报告中。该经纪公司对该股设定了 “卖出” 评级。
BiondVax Pharmaceuticals Trading Up 7.6 %
BiondVax 制药交易价格上涨7.6%
NASDAQ BVXV opened at $2.82 on Monday. The business's fifty day moving average is $6.78 and its 200-day moving average is $8.93. The company has a debt-to-equity ratio of 5.92, a current ratio of 5.76 and a quick ratio of 5.76. The stock has a market capitalization of $4.04 million, a price-to-earnings ratio of -0.70 and a beta of 2.65. BiondVax Pharmaceuticals has a one year low of $2.37 and a one year high of $22.90.
纳斯达克BVXV周一开盘价为2.82美元。该公司的五十天移动平均线为6.78美元,其200天移动平均线为8.93美元。该公司的债务与权益比率为5.92,流动比率为5.76,速动比率为5.76。该股的市值为404万美元,市盈率为-0.70,beta值为2.65。BiondVax Pharmicals创下一年低点2.37美元,一年高点为22.90美元。
BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its quarterly earnings data on Wednesday, November 30th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Equities research analysts predict that BiondVax Pharmaceuticals will post -0.3 EPS for the current year.
BiondVax Pharmicals(纳斯达克股票代码:BVXV — 获取评级)最后一次公布其季度收益数据是在11月30日星期三。该公司报告本季度每股收益0.06美元,比市场普遍预期的(0.10美元)高出0.16美元。股票研究分析师预测,BiondVax Pharmicals今年每股收益将为-0.3。
Hedge Funds Weigh In On BiondVax Pharmaceuticals
对冲基金对 BiondVax 制药进行权衡
BiondVax Pharmaceuticals Company Profile
BiondVax 制药公司简介
(Get Rating)
(获取评分)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
BiondVax Pharmicals Ltd. 是一家处于开发阶段的生物制药公司,专注于开发、制造和商业化用于预防和治疗以色列传染病和其他疾病的产品。该公司与马克斯·普朗克协会和哥廷根大学医学中心签订了许可和合作协议,用于 COVID-19 纳米抗体(nanoAB)的开发和商业化;以及用于其他各种疾病适应症的nanoAB的开发和商业化。
See Also
另见
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- 免费获取 StockNews.com 关于 BiondVax Pharmicals (BVXV) 的研究报告的副本
- 通用电气股票,所有零件之和策略正在获得回报
- MarketBeat:本周回顾 01/09-01/13
- 随着银行为衰退做准备,摩根大通下跌
- 为什么 Bed Bath & Beyond 的股价上涨了 261%?
- Roku 股价正在走势,原因如下
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 BiondVax 制药日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收BiondVax Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧